PCI Pharma Services Commits Over $1 Billion to Expand Sterile Fill-Finish and Drug-Device Capabilities Across the US and Europe.

PCI is investing over $1 billion in US and European infrastructure to expand sterile fill-finish, advanced drug delivery, and contract manufacturing. The goal is to bolster US-based supply chain resilience and offer integrated services from clinical development to commercial production.

It reinforces the ability to provide seamless support for drug product development and manufacturing, clinical trial supply, and drug-device combination assembly from clinical stages through commercial launch. 

According to Towards Healthcare, the U.S. liquid vaccine filling solutions market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 1.56 billion in 2026 to approximately USD 3.63 billion by 2035, representing a compound annual growth rate (CAGR) of 9.85% from 2026 to 2035. Growth is driven by the increasing vaccine production capacity to meet rising demand for infectious diseases, combined with a focus on manufacturing efficiency and technological advancement in aseptic processing, automation, and the integration of robotics in filling operations, which ensures high quality and sterility. 

Investments in Drug-Device Combination Assembly and Packaging Platforms 

PCI has committed in partnership with leading device manufacturers for numerous buildouts of autoinjector and drug-device combination assembly infrastructure at its campuses in Philadelphia, PA, and Rockford, IL. Coming online via a phased approach over the next six months, the upgrades will significantly increase both capacity and scale, bolstering PCI’s integrated, clinical-through-commercial capabilities. 

Philadelphia and Rockford are also home to PCI's US Packaging Centres of Excellence, which offer ample capacity for oral solid dose and injectable products, as well as substantial cold chain storage. The company’s autoinjector lines provide comprehensive high-speed assembly, while a dedicated prefilled syringe (PFS) safety device line adds labelling and secondary packaging options. 

About PCI Pharma Services 

It focuses on delivering life-changing therapies by combining expertise, technology, and innovation. Mission emphasised on improving patient outcomes while supporting clients with scalable, compliant, and efficient pharmaceutical solutions.  

Its integrated global network allows clients to reduce complexity, accelerate time-to-market, and maintain continuity from clinical trials to commercial supply. It provides pharmaceutical development, manufacturing, packaging, and logistics services, supporting clients from early-stage clinical development through global commercialisation. 

The company currently has 38 sites across seven countries (the United States, Canada, the United Kingdom, Ireland, Germany, Spain, and Australia), and over 7,500 employees working to bring life-changing therapies to patients. 

A recent report by Towards Healthcare highlights that the U.S. liquid vaccine filling solutions market is witnessing growth due to the high demand for vaccine distribution infrastructure, pandemic preparedness, and specialised storage requires advanced, sterile, and fast filling solutions for an automated system to ensure accuracy and reduce contamination risks.